Pfizer Earnings - What Jim Cramer Wants to Hear From the FDA
Pfizer (PFE) - Get Free Report reported adjusted earnings per share of $1.07 on revenue of $19 billion. Pfizer said its coronavirus vaccine sales would reach at least $33.5 billion this year.
On the subject of the COVID vaccine, Pfizer also provided an update on the booster shot it has in development. Pfizer included trial data showing a booster shot can "strongly" boost protection from the delta variant of the coronavirus.
As of yet, no U.S. regulatory health authority has announced a need for a booster shot, though.
"Americans who have been fully vaccinated do not need a booster shot at this time. FDA, CDC, and NIH are engaged in a science-based, rigorous process to consider whether or when a booster might be necessary," the FDA, NIH and CDC said in a joint release in early July.
Jim Cramer said the ball is in the FDA's court when it comes to a booster shot from Pfizer in the video above.
Recap TheStreet Live: Everything Jim Cramer Is Watching 7/28
Hear what Jim Cramer is only telling members of his Action Alerts PLUS investing club in Wednesday's Daily Rundown.
